Johnson & Johnson: Cognitive Dysfunction trials
The registry lists 11 Cognitive Dysfunction studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 2 have results posted.
Early Phase 1 1Phase 2 1Phase 3 5Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of JNJ-63733657 in Participants With Early Alzheimer's DiseaseTerminatedNCT04619420Phase 2Results posted
- An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00814801Phase 3Results posted
- A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive ImpairmentCompletedNCT02419183
- A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's DiseaseCompletedNCT01436188Early Phase 1
- An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.CompletedNCT00301574Phase 3
- An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of GalantamineCompletedNCT00297414
- Prospective Research in Memory Clinics (PRIME)CompletedNCT00297271
- A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentCompletedNCT00236574Phase 3
- A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentCompletedNCT00236431Phase 3
- A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.CompletedNCT00077727Phase 3
- A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's DiseaseCompletedNCT00035204Phase 4